Viron is a privately held, clinical stage biopharmaceutical company focused upon the commercialization of novel anti-inflammatory therapeutics.  In order to rapidly generate shareholder value, Viron's business model commits to an aggressive development of therapies for various human inflammatory diseases.  Viron is focused on the development of viral proteins as a sustainable and unexploited source of therapeutic candidates. Viron's rapidly developing product pipeline and intellectual property portfolio consist of an entirely novel class of therapies. This approach provides enormous competitive advantages to Viron by providing numerous unique product development opportunities.

Viron secured a $20M Series A round of financing in 2006 with a strong group of international investors including:

The investment will finance the company operations well into 2008, enabling it to achieve a number of significant development milestones, including the completion of an ongoing Phase II clinical trial, the advancement of its next clinical candidate, a potent TNF-α inhibitor, and the scale up and optimization of its manufacturing process to prepare for market launch and further reduce cost of goods. Resources will also be allocated to the discovery process to ensure that Viron continues to exploit its sustainable platform by increasing the number of pipeline compounds beyond the current 7 drug candidates.

Inquiries

Should you be interested in discussing investment opportunities, please contact:

James M. Rae
President & CEO

By Email:  This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

By Mail:

Viron Therapeutics Inc.

700 Collip Circle, Suite 203

London, ON  Canada

N6G 4X8

By Telephone:  519.858.5109

By FAX:  519.858.5103